Evidence map›Paper›PMID 37991639›Full record

ArticleEJNMMI radiopharmacy and chemistry2023

Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [

Emma Jussing, Mélodie Ferrat, Mohammad M Moein, Henrik Alfredéen, Tetyana Tegnebratt, Klas Bratteby, Erik Samén, Joachim Feldwisch, Renske Altena, Rimma Axelsson and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05619016 (Phase II Study of [68Ga]Ga-ABY-025 PET for Non-invasive Quantification of HER2-status in Solid Tumors), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05619016 phase2unknown statusnot on this map

Phase II Study of [68Ga]Ga-ABY-025 PET for Non-invasive Quantification of HER2-status in Solid Tumors

TypeinterventionalSponsorKarolinska University HospitalRan2022 to 2025Enrolled72ConditionsEsophageal Neoplasms, Gastric Neoplasms Malignant, Breast Cancer, HER2-positive Gastric CancerArms[68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2 expression
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Emma JussingDepartment of Radiopharmacy, Karolinska University Hospital, 171 76, Stockholm, Sweden. emma.jussing@ki.se.ORCID http://orcid.org/0000-0003-4697-732X
Mélodie FerratDepartment of Radiopharmacy, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Mohammad M MoeinDepartment of Radiopharmacy, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Henrik AlfredéenDepartment of Radiopharmacy, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Tetyana TegnebrattDepartment of Radiopharmacy, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Klas BrattebyDepartment of Radiopharmacy, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Erik SaménDepartment of Radiopharmacy, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Joachim FeldwischAffibody AB, 171 65, Solna, Sweden.
Renske AltenaDepartment of Oncology and Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
Rimma AxelssonDepartment of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, 171 76, Stockholm, Sweden.
Thuy A TranDepartment of Radiopharmacy, Karolinska University Hospital, 171 76, Stockholm, Sweden.

Funding

Sjöbergsstiftelsen 929649
6 · The paper itself

Abstract

backgroundThe Affibody molecule, ABY-025, has demonstrated utility to detect human epidermal growth factor receptor 2 (HER2) in vivo, either radiolabelled with indium-111 (

resultsA simplified and optimized automated cGMP-compliant radiosynthesis method of [

conclusionThe improvements made for the radiosynthesis of [

trial registrationNCT, NCT05619016, Registered 7 November 2022, https://clinicaltrials.gov/study/NCT05619016?term=HER2&cond=ABY025&rank=1.

Indexed as

[68Ga]Ga-ABY-025ABY-025AffibodyBreast cancerGallium-68HER2 lowHER2-PET imagingHuman Epidermal growth factor Receptor 2

Identifiers

PMID37991639
PMCPMC10665286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.